Menu
Capabilities
37 Years of Know-How & continuing to innovate to stay on the leading edge
Alpex Pharma develops end-to-end pharmaceutical and nutraceutical solutions. We develop pharmaceutical drugs and products while simultaneously deploying the innovative and patented technologies used for their administration.
We are an integrated pharma company providing a wide range of services to our clients and partners with an unflinching focus on quality and reliability. Our high-production capacities and advanced R&D technologies make us one of the most important companies in the field of fast-melt ODT’s (oral dissolving tablets) in the world.
Our drug delivery systems and dosage forms maximise the utility drawn from our drug’s API’s (Active Pharmaceutical Ingredients), promoting successful treatments based on precise dosage and efficient delivery, giving more control to medical practitioners and reducing the need for redundancy during manufacture.
With 100+ patents, we have commercialised over 150 different products and successfully established ourselves as a standard in the healthcare industry with more than 200 million units sold annually. A Swiss-based global company, our pharmaceuticals, innovative medicines, nutraceuticals, and delivery systems are sold across the globe’s most demanding markets. By operating in a highly regulated sector, we adopt a high-watermark approach to compliance to ensure that we exceed the requirements of all applicable international standards.
Our Industry-Explicit Competence
We are an integrated pharma company. And in addition to our key activities, we provide a wide range of services to our clients and partners. doing so with an rigourous focus on quality and reliability. Our high production capacities and advanced R&D technologies make us one of the most important companies in the field of fast-melt ODT’s (oral dissolving tablets) in the world.
on the leading edge of pharmaceuticals over the past four decades
Our company was born in 1988 as Aesculapius Pharma with a focus on effervescent formulations. Four years later, Aesculapius was acquired by Élan Pharma, during which we developed and commercialised the world’s first fast-melt product. In 2004, the company’s majority shares were acquired by Sanders, Morris, Harris (SMH) funds, and was rebranded as Alpex Pharma SA. In the following years, we developed and distributed dozens of innovative drugs and supplements in Europe, the Americas, and Australia. In 2021, Alpex broke ground on facility expansion for further global growth, and launched projects focusing on longevity and novel medicine development.
As a research-based pharmaceutical company, we’re driving rapid growth and combating disease by developing innovative medicinal products.
Alpex is uniquely positioned with both Nutraceutical & Pharma R&D & Production under one roof enabling our partners to migrate and focus across both sectors with the same partner.
Pharma companies are increasingly seeking to develop nutraceutical formulations and new products to tap into the explosive consumer spending on preventative health.
We are developing proprietary Life-Extending formulations to support the global ageing populations in longevity and capitalise on the quickly growing market.
We invest heavily in developing, deploying, and scaling novel medicines and supplements to address high-growth segments in pharma, nutraceuticals, and longevity.
Developing life-changing treatments for the world’s rarest ailments.
As a research-based pharmaceutical company, we’re driving rapid growth and combating disease by developing innovative medicinal products.
Alpex is uniquely positioned with both Nutraceutical & Pharma R&D & Production under one roof enabling our partners to migrate and focus across both sectors with the same partner.
Pharma companies are increasingly seeking to develop nutraceutical formulations and new products to tap into the explosive consumer spending on preventative health.
We are developing proprietary Life-Extending formulations to support the global ageing populations in longevity and capitalise on the quickly growing market.
We invest heavily in developing, deploying, and scaling novel medicines and supplements to address high-growth segments in pharma, nutraceuticals, and longevity.
Developing life-changing treatments for the world’s rarest ailments.